Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in previously untreated mantle cell lymphoma
2023-509354-58-00Phase 3Authorised
- Sponsor
- Acerta Pharma
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Acalabrutinib plus bendamustine and rituximab with Placebo plus bendamustine and rituximab (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2017; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-509354-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509354-58-00.